Apple Ordered to Pay $634 Million to Masimo Over Patent Infringement
A federal jury in California has ruled that Apple must pay $634 million to medical device manufacturer Masimo for infringing upon a patent related to blood oxygen-monitoring technology. This decision highlights the fierce competition and legal battles between tech companies and specialized firms in the healthcare sector.
Details of the Case
The jury determined that specific features of the Apple Watch, particularly its workout mode and heart rate notifications, violated Masimo’s patent. This ruling has significant implications for Apple as it continues to expand its health monitoring functionalities.
Masimo expressed their satisfaction with the verdict, stating, “This is a significant win in our ongoing efforts to protect our innovations and intellectual property, which is crucial to our ability to develop technology that benefits patients.” The company remains steadfast in defending its intellectual property rights in future disputes.
Apple’s Response
In response to the jury’s decision, an Apple spokesperson described the verdict as “contrary to the facts” and confirmed plans to appeal. The spokesperson further noted that Masimo, a medical device company that does not sell products directly to consumers, has pursued multiple legal actions against Apple over the past six years, asserting over 25 patents, most of which have been deemed invalid. The spokesperson emphasized that the specific patent at issue expired in 2022 and pertains to older patient monitoring technologies.
Pulse Oximetry Legal Conflict
The ongoing legal battle between Masimo and Apple centers on pulse oximetry technology, which utilizes an optical sensor to measure blood flow. Masimo has accused Apple of hiring key employees, including its former chief medical officer, and infringing on their patents regarding this technology.
In a related development, the U.S. International Trade Commission ruled in favor of Masimo in 2023, barring Apple from importing Apple Watches featuring blood oxygen-monitoring capabilities. As a result, recent Apple Watches have not supported blood oxygen monitoring due to this ban.
Changes in Apple’s Product Strategy
In August of this year, Apple revealed plans to introduce a revamped version of its blood oxygen monitoring feature. Instead of facilitating measurements directly on the smartwatch, the new system calculates readings using paired iPhones, aiming to comply with the import regulations.
In a further twist, Masimo has filed a lawsuit against U.S. Customs and Border Protection for allowing the importation of Apple Watches that implement this adjusted blood oxygen measurement method. Meanwhile, Apple is actively seeking to overturn the import ban via an appeals court.
Counterclaims and Legal Maneuvering
Apple has also countersued Masimo, resulting in a jury verdict that awarded Apple the statutory minimum of $250 after finding Masimo had violated Apple’s design patents.
Conclusion
The ongoing conflict between Apple and Masimo illustrates the complexities of IP rights within the tech industry, particularly in health technology. With substantial financial stakes and reputational implications, the outcome of Apple’s appeal will be keenly awaited by both companies and the broader tech sector.
For more information on patent rights and the implications of technology in healthcare, check out resources from WIPO and USPTO.
